OXYGENTA PHARMACEUTICAL LIMITE Share Price

OXYGENTA PHARMACEUTICAL LIMITE Share Price

BSE: 524636
|
Pharmaceuticals
|
S Cap
₹ 50.01
-₹0.39 (-0.77%)
1D
Last updated 23 Sep, 2026, 15:26 IST

OXYGENTA PHARMACEUTICAL LIMITE Share Price Today

As of 23 Sep 2026, OXYGENTA PHARMACEUTICAL LIMITE share price is ₹50.01. The stock opened at ₹50.39, compared to its previous close of ₹50.40. During today's trading session, OXYGENTA PHARMACEUTICAL LIMITE share price moved in the range of ₹48.11 to ₹50.69, with an average price of ₹49.40 for the day. Looking at its last 52-week, the stock has touched a low of ₹43.00 and a high of ₹74.00.

₹48.11
0.77% down today
₹50.69
1D LOW
1D HIGH

OXYGENTA PHARMACEUTICAL LIMITE Returns Calculator

Circuit
L
H
₹47.88
₹52.92
52-week
L
H
₹43.00
₹74.00

About OXYGENTA PHARMACEUTICAL LIMITE

OXYGENTA PHARMACEUTICAL LIMITE Share Price
ISIN
INE102E01018
Sector Market Cap
₹ 196.20 Cr

Oxygenta Pharmaceutical Limited is an India-based company engaged in the manufacturing and selling of pharmaceutical, medical and veterinary preparations. It operates in the pharmaceutical segment. The Company also sells the products to its related companies engaged in the manufacture of formulations. Its active pharmaceutical ingredients (API) products include pantoprazole sodium, vildagliptin, telmisartan, lacosamide, and sertraline hydrochloride. The Company’s chemical products include 3-Amino-1-adamantanol, (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile, 2-N-Propyl-4-methyl-6-(1-methyl benzimidazole-2-yl) benzimidazole, Isobutyramide, 4-Aminobenzonitrile, Valeronitrile and others. Its manufacturing facilities are situated at Sadasivapet Mandal, Sangareddy District, Telangana State.

OXYGENTA PHARMACEUTICAL LIMITE Financial Highlights

  • Revenue: OXYGENTA PHARMACEUTICAL LIMITE reported revenue of ₹113.27 crore in FY26 vs ₹110.61 crore in FY25. It showed an increase of 2.40% on a yearly basis.
  • Operating Profit: OXYGENTA PHARMACEUTICAL LIMITE reported an operating loss of ₹22.18 crore in FY26 vs ₹14.35 crore in FY25. It showed a decrease of 54.56% on a year-on-year basis.
  • Net Profit: OXYGENTA PHARMACEUTICAL LIMITE reported a net loss of ₹17.57 crore in FY26 vs ₹10.30 crore in FY25. It showed a decrease of 70.58% on a yearly basis.

OXYGENTA PHARMACEUTICAL LIMITE Quarterly Result Highlights

  • OXYGENTA PHARMACEUTICAL LIMITE reported revenue of ₹37.02 crore in Jun 2026, compared with ₹49.78 crore in Mar 2026, representing a decrease of 25.63% on a quarter-on-quarter (QoQ) basis.
  • OXYGENTA PHARMACEUTICAL LIMITE reported an operating loss of ₹2.51 crore in Jun 2026, compared with ₹1.28 crore in Mar 2026, representing a decrease of 96.09% on a quarter-on-quarter (QoQ) basis.
  • OXYGENTA PHARMACEUTICAL LIMITE reported a loss of ₹2.10 crore in Jun 2026, compared with ₹1.70 crore in Mar 2026, reflecting a decrease of 23.53% on a QoQ basis.
  • The earnings per share (EPS) of OXYGENTA PHARMACEUTICAL LIMITE stood at ₹4.75 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
56.54%
FII
0.00%
Other DII
0.00%
Retail and other
43.44%
Mutual funds
0.03%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 20250.00%
Dec 20250.00%
Mar 20260.00%
Jun 20260.00%
Mkt Cap Cr
186.40
P/E
-13.73
P/B
-4.19
ROE
41.16%
D/E
-2.57
ROCE
-26.02%
Div. Yield
0.00%
EPS(TTM)
-4.75
Turnover
1.13
EV/EBITDA
-38.68
Net Margin
-15.55%
Op. Margin
-13.31%
ROA
-11.34%
Quick Ratio
0.26
Curr. Ratio
0.99
Based on fundamentals, this stock's
Step 1 of 5
Performance
Very Poor
Oxygenta Pharma has not beaten FD return of 7%
Step 1 of 5
Valuation
Overvalued
Oxygenta Pharma appears overvalued compared to its peers
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,42,437.0036.515.2913.74%0.6117.33%93.240.87%0.4810.90
Divis Laboratories2,48,054.0084.8114.8015.32%0.0019.56%629.490.32%0.5598.19
Torrent Pharmaceuticals1,89,842.0088.0622.5725.49%1.6913.85%222.760.68%0.4958.70
Zydus Lifesciences1,15,810.0025.224.2718.59%0.3117.35%237.300.09%0.3335.38
Cipla1,11,565.0033.253.2411.27%0.0014.95%423.360.94%0.4543.52
Laurus Labs1,08,338.0099.3620.4416.77%0.4016.14%97.200.10%0.6713.72
Mankind Pharma1,02,410.0049.536.2811.74%0.3413.13%396.980.04%0.4449.37
Dr. Reddy's Laboratories1,01,163.0031.782.6611.07%0.1812.54%377.950.66%0.4138.68
Aurobindo Pharma97,641.6026.312.589.25%0.1911.76%394.820.24%0.3841.58
Lupin96,950.0017.474.3223.76%0.0424.88%658.960.85%0.57129.18

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

OXYGENTA PHARMACEUTICAL LIMITE Financials

Full statement

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹112.98₹109.30₹39.64₹30.99
Other Income₹0.29₹1.31₹0.04₹0.02
Total Revenue₹113.27₹110.61₹39.68₹31.01
Total Expenses₹135.45₹124.96₹53.59₹41.64
Profit Before Tax-₹22.18-₹14.35-₹13.87-₹11.37
Tax-₹4.61-₹4.05-₹10.39₹0.20
Profit After Tax-₹17.57-₹10.30-₹3.48-₹11.57
EPS - Basic-₹4.75-₹2.86-₹1.09-₹8.15
EPS - Diluted-₹4.75-₹2.86-₹1.04-₹8.15

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax-₹22.18-₹14.35-₹13.87-₹11.37
Income before WC changes-₹14.15-₹7.75-₹9.56-₹7.84
Change in Assets-₹19.41-₹7.63₹1.25-₹15.54
Change in Liabilities₹5.65₹18.21-₹4.73₹21.75
Change in WC-₹13.76₹10.58-₹3.49₹6.20
Cash flow from Operations-₹27.75₹2.83-₹13.05-₹1.63
Cash flow from Investing-₹14.39-₹11.32-₹4.09-₹9.64
Cash flow from Financing₹42.56₹8.49₹17.13₹11.22
Total Cash Flow₹0.42₹0.00-₹0.01-₹0.05
Cash (Start of the year)₹0.00₹0.00₹0.11₹0.16
Cash (End of the year)₹0.42₹0.00₹0.10₹0.11

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹68.25₹51.86₹39.09₹29.26
Current Assets₹51.43₹30.94₹24.11₹25.01
Total Assets₹119.68₹82.80₹63.19₹54.26
Current Liabilities₹86.10₹85.85₹33.70₹32.90
Net Current Asset-₹34.67-₹54.90-₹9.59-₹7.89
Non-Current Liabilities₹76.27₹22.60₹49.62₹67.57
Equity Capital-₹42.69-₹25.64-₹20.12-₹46.20
Total Equity & Liabilities₹119.68₹82.80₹63.19₹54.26
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
0
0
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 0
Buy orders: 0%
Sell orders: 0%
Bearish
2
Neutral
3
Bullish
3
Slightly Bullish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
36.3
Neutral
ATR (14)
2.83
Neutral
STOCH(9,6)
0
Bullish
STOCH RSI (14)
0
Bullish
ADX(9)
21.9
Bearish
UO(9)
35.6
Neutral
ROC(12)
-9.89
Bearish
WillR(14)
-100
Bullish
Period
Simple value
Exponential vaue
5D
52.48
52.35
10D
53.54
53.37
20D
55.09
54.76
50D
55.21
54.9
100D
53.05
54.05
Volume trend — traded volume by day
23 Sep0L
22 Sep0L
21 Sep0L
18 Sep0L
17 Sep0L
16 Sep0L
Average0L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
OXYGENTA PHARMACEUTICAL LIMITE Share Price
OXYGENTA PHARMACEUTICAL LIMITE
Pharmaceuticals
Add Stock
Add Another

OXYGENTA PHARMACEUTICAL LIMITE Share Price FAQs

OXYGENTA PHARMACEUTICAL LIMITE share price data is sourced from NSE/BSE and may be delayed. It is displayed for informational purposes only and does not constitute investment advice or a recommendation to buy or sell.

Trusted by 2 Crore+ Indians for their wealth-building needs. SEBI Registered Broker. SEBI Reg No. INZ000315837